The most likely indicator of whether biotech’s Wall Street hot streak can last is whether investors are getting good returns on all these drug developer IPOs. And so far, the beneficiaries of 2014’s boomlet are coming through.

…read more

Source: Biotech IPOs: Class of 2014 still rolling as investors line up to cash in


0 No comments